In the landmark EXALT-1 clinical study, our platform demonstrated for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial.

EXALT-1 is the ﬁrst-ever prospective interventional study of its kind. Predictions made by the platform proposed which therapy would be most effective for late stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples.   

EXALT-1 demonstrated real-world patient selection capabilities by achieving a 55% response rate and statistically significant improvement in progression free survival over the prior line of therapy for patients that were treated following the platform’s recommendation.  

EXALT-1 Trial